转化生物医学

  • 国际标准期刊号: 2172-0479
  • 期刊 h 指数: 16
  • 期刊引用分数: 5.91
  • 期刊影响因子: 3.66
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 研究圣经
  • 全球影响因子 (GIF)
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Synthetic Biology in Drug Discovery as a Source of Discovery in Translation Biomedicine

Kevin Buja

The declining cost of DNA synthesis, improvements in genetic engineering, expanding knowledge of genome organisation, and boom in data science, the influence of synthetic biology on the world has been escalating [1]. But a lot of the discipline's use in the pharmaceutical sector is still unclear. The influence of synthetic biology on target validation, assay development, hit discovery, lead optimization, chemical synthesis, and the creation of cellular therapies is highlighted in this review's current examples. We also emphasise the accessibility of the technology and resources powering the field [2]. All phases of drug discovery and development are undoubtedly impacted by synthetic biology, and the prospects for the drug discovery and development value chain may grow as a result of the discipline's contribution being acknowledged [3].

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证